Incyte (NASDAQ:INCY – Get an assessment) was raised by TheStreet equity researchers from a “c+” rating to a “b” rating in a research note released on Monday, TheStreetRatingsTable reports.

A number of other analysts have also published reports on the company. Zacks Investment Research downgraded Incyte from a “sell” to a “hold” rating and set a price target of $85.00 on the stock in a Tuesday, April 5 research note. SVB Leerink downgraded Incyte from a “market performer” rating to an “underperformer” rating and lowered its price target for the stock from $60.00 to $56.00 in a research note Wednesday, February 9. Royal Bank of Canada upgraded Incyte from a ‘sector performance’ rating to an ‘outperform’ rating and raised its price target for the stock from $78.00 to $90.00 in a research note Tuesday, January 18. Guggenheim lowered its price target on Incyte from $118.00 to $104.00 in a Monday, Jan. 3 research note. Finally, Morgan Stanley cut its price target on Incyte from $77.00 to $76.00 and set an “equal weight” rating on the stock in a Wednesday, Feb. 2 research note. One equity research analyst gave the stock a sell rating, four gave the stock a hold rating, six gave the stock a buy rating and one gave the stock a high buy rating. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $87.82.

NASDAQ:INCY shares opened at $79.47 on Monday. The company has a debt ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.62. The company’s 50-day moving average price is $74.51 and its 200-day moving average price is $71.12. The company has a market capitalization of $17.59 billion, a PE ratio of 18.61, a P/E/G ratio of 0.90 and a beta of 0.73. Incyte has a 1-year low of $61.91 and a 1-year high of $88.26.

Incyte (NASDAQ:INCY – Get Rating) last released its quarterly results on Tuesday, February 8. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing Zacks’ consensus estimate of $0.65 per ($0.72). The company posted revenue of $862.50 million in the quarter, versus analyst estimates of $813.38 million. Incyte had a return on equity of 14.66% and a net margin of 31.76%. The company’s revenue increased 9.4% year over year. In the same period a year earlier, the company earned earnings per share of $0.73. As a group, analysts expect Incyte to post earnings per share of 2.52 for the current year.

In other news, Executive Vice President Jonathan Elliott Dickinson sold 7,375 shares of the company in a trade dated Monday, January 31. The stock was sold at an average price of $74.19, for a total transaction of $547,151.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this link. Additionally, Executive Vice President Barry P. Flannelly sold 43,993 shares of the company in a transaction dated Friday, April 8. The shares were sold at an average price of $83.49, for a total value of $3,672,975.57. Following the completion of the sale, the executive vice president now directly owns 65,163 shares of the company, valued at $5,440,458.87. The disclosure of this sale can be found here. Over the past ninety days, insiders have purchased 711,335 shares of the company valued at $49,689,821. Insiders hold 15.80% of the shares of the company.

Several hedge funds and other institutional investors have recently changed their positions in INCY. National Bank of Canada FI acquired a new stake in Incyte during the 4th quarter for a value of approximately $44,000. Illinois Municipal Retirement Fund increased its position in Incyte by 30.9% during the fourth quarter. The Illinois Municipal Retirement Fund now owns 21,033 shares of the biopharmaceutical company worth $1,544,000 after acquiring 4,961 additional shares during the period. Frontier Capital Management Co. LLC acquired a new stake in Incyte during Q4 valued at approximately $5,774,000. QCI Asset Management Inc. NY increased its position in Incyte by 5.0% during the third quarter. QCI Asset Management Inc. NY now owns 251,161 shares of the biopharmaceutical company worth $17,275,000 after acquiring an additional 11,980 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its position in Incyte by 28.2% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 165,298 shares of the biopharmaceutical company worth $12,215,000 after acquiring an additional 36,381 shares during the period. 91.33% of the shares are held by hedge funds and other institutional investors.

Incyte Company Profile (Get a rating)

Incyte Corporation, a biopharmaceutical company, is focused on the discovery, development and commercialization of proprietary therapeutic products in the United States and around the world. The company offers JAKAFI, a medicine for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that acts as an oncogenic inducer in various types of liquid and solid tumors; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Recommended Stories

Get news and reviews for Incyte Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Incyte and related companies with MarketBeat.com’s free daily email newsletter.